| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/10-1/50 | Human,Mouse,Rat |
| FCM | 1/10-1/50 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Calcitonin receptor, CT-R, CALCR |
| Entrez GeneID | 799 |
| WB Predicted band size | 55.3kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This CALCR antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 465-494 amino acids of human CALCR. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇与CALCR(降钙素受体)抗体相关的文献示例(注：文献信息为模拟示例，实际引用请核实原文)：
1. **《CALCR antibody as a novel biomarker in medullary thyroid carcinoma》**
- **作者**: Rossi, G. et al.
- **摘要**: 研究验证了CALCR抗体在甲状腺髓样癌(MTC)组织中的特异性表达，表明其可作为辅助诊断标志物，并通过免疫组化证实CALCR与肿瘤侵袭性相关。
2. **《Targeting CALCR in osteoclast differentiation: Insights from monoclonal antibody modulation》**
- **作者**: Lee, S. & Kim, H.
- **摘要**: 利用CALCR抗体阻断受体功能，发现其可抑制破骨细胞分化，提示靶向CALCR或为骨质疏松症治疗提供新策略。
3. **《Dual role of CALCR antibodies in cancer progression and bone metastasis》**
- **作者**: Zhang, Y. et al.
- **摘要**: 通过体内实验证明，CALCR抗体既能抑制乳腺癌细胞迁移，又可调节骨微环境，减少转移灶形成，揭示其双重治疗潜力。
如需具体文献，建议通过PubMed或Google Scholar搜索关键词“CALCR antibody”“calcitonin receptor immunohistochemistry”等获取最新研究。
The calcitonin receptor (CALCR), a class B G protein-coupled receptor (GPCR), plays a critical role in calcium homeostasis, bone metabolism, and cellular signaling. It binds calcitonin, a hormone produced by thyroid C-cells, and related peptides like amylin and adrenomedullin, activating downstream pathways (e.g., cAMP, MAPK) to regulate osteoclast activity, renal calcium excretion, and other physiological processes. CALCR antibodies are tools developed to detect, quantify, or modulate receptor expression and function in research and clinical contexts.
These antibodies are widely used in immunohistochemistry, Western blotting, and flow cytometry to study CALCR distribution in tissues such as bone, kidney, and brain. In oncology, CALCR overexpression is linked to malignancies like medullary thyroid carcinoma and breast cancer, making its antibodies valuable for diagnostic staining or therapeutic targeting. In bone disorders (e.g., osteoporosis, Paget’s disease), CALCR antibodies help elucidate receptor dynamics during bone resorption or anabolic therapies.
Therapeutic anti-CALCR agents, though still experimental, aim to block pathological signaling or deliver targeted drugs. Challenges include ensuring specificity due to structural similarities among GPCRs and optimizing antibody penetration in dense tissues. Overall, CALCR antibodies bridge mechanistic studies and translational applications, offering insights into metabolic diseases, cancer progression, and receptor biology.
×
